Array Biopharma, Inc. (ARRY) Reports Q1 EPS Loss of $0.06, Sales Beat Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.19 -3.33%
Revenue Growth %: -18.0%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -18.0%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.06), $0.13 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $17.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Array Technologies (ARRY) PT Lowered to $6 at BMO Capital
- Schlumberger Ltd. (SLB) Tops Q3 EPS by 2c, Beats on Revenue
- American Express (AXP) Tops Q3 EPS by 84c, Misses on Revenue, Raises FY Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
